Spain’s medicines agency recommends that women who use Mounjaro and the contraceptive pill use additional protection against pregnancy. They should also use a barrier method such as a condom for four weeks after starting treatment and after every dose increase. Alternatively, they could switch to a non-oral contraceptive method.
The agency AEMPS published the updated guidance on 19 November 2026. It says the reason is that only limited information is available on how the active ingredient in Mounjaro, tirzepatide affects the absorption and effectiveness of oral contraceptives in women with obesity, overweight or type 2 diabetes .
The recommendation is a precautionary measure. The statement does not give a likelihood of the pill failing during treatment. The limited data therefore do not make it possible to derive a specific failure rate. Patients can discuss the contraceptive method that is right for them with their treating doctor.
Mounjaro is used to treat type 2 diabetes and for weight management in adults. For weight management, it is intended for people with obesity and for people who are overweight and have at least one weight-related condition. The medicine is injected; the new recommendation concerns the simultaneous use of contraceptives that are taken orally.
According to the Spanish statement, two committees of the European Medicines Agency have reviewed the available information and updated the recommendations. Following a decision by the European Commission, the marketing authorisation holder is to inform healthcare professionals by letter. The recommendations are also to be included in the product information and package leaflet for medicines containing tirzepatide.
According to AEMPS, it was already the case that tirzepatide is not recommended during pregnancy or for women who could become pregnant and are not using contraception. Anyone planning a pregnancy should stop treatment at least one month beforehand. If pregnancy occurs during treatment, tirzepatide should be discontinued.
The new guidance relates to tirzepatide. By contrast, the medicines also used to treat metabolic conditions or for weight management, Ozempic and Wegovy contain the active ingredient semaglutide. The Spanish agency’s statement does not indicate that the specific recommendation also applies to these medicines.
Editor: Clara Simonichek (Article created with AI assistance).